People News

U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

4.0 from 1 vote
Tuesday, June 19, 2018

NEW YORK, USA and MELBOURNE, Australia -  Mesoblast Limited (ASX: MSB; Nasdaq: MESO) announced that Joseph R. Swedish has joined its Board of Directors. Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc. (NYSE: ANTM), a Fortune 33 company and the leading health benefits provider in the U.S.

Prior to joining Anthem, Mr Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado’s Centura Health. He currently serves on the Board of Directors for IBM Corporation, CDW Corporation, and Proteus Digital Health. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare.

Commenting on his appointment, Mr Swedish stated: “I am very pleased to join the Board of Mesoblast, a leading cell therapy company whose strategy is consistent with my objectives to deliver innovative, cost-effective solutions to some of the most pressing healthcare challenges today.”

Mesoblast Chairman Brian Jamieson said: “Mr Swedish’s strong record of understanding U.S. healthcare resource allocation and reimbursement metrics is in line with the Board’s objective to strengthen its commercial focus. Mr Swedish replaces Dr Ben-Zion Weiner, who we thank for his valuable contributions to Mesoblast over the past five years, especially in relation to our research and development pipeline.”
Ignite Partners advised Mesoblast on the appointment of Mr Swedish.

About Mesoblast
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a global leader in developing innovative cell-based medicines. Through a proprietary process, Mesoblast selects highly purified mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults, and creates master cell banks which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off the shelf without the need for tissue matching.

The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates are being evaluated in their ability to target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Mesoblast Inc.
505 Fifth Avenue
Level 3
New York, NY 10017

TFN: 1 844 889 MESO
TFN: 1 844 889 6376
T: +1 212 880 2060
F: +1 212 880 2061

Source: Mesoblast Limited
4.0 from 1 vote
Free Newsletter
by Abidemi Uruejoma
by Abidemi Uruejoma